An analysis presented at the AMCP 2025 Annual Meeting assessed uptake trends for the bevacizumab biosimilar in patients with non-small cell lung cancer (NSCLC) and metastatic colorectal cancer (mCRC) and found that use increased over time, while use of the originator biologic declined. Both the biosimilar and originator agent appeared to induce similar outcomes.
The bevacizumab biosimilar launched in 2019. The non-interventional, retrospective study used deidentified data from Carelon Research’s Healthcare Integrated Research Database from July 1, 2017, to March 31, 2024.
The cohort included 1,307 patients with NSCLC (53.6% female; 83.6% non-Hispanic/Latino white; median age, 67 years) and 4,688 with mCRC (43.4% female; 78.6% non-Hispanic/Latino white; median age, 59 years).
In the NSCLC cohort, the proportion of patients using:
- The biosimilar agent increased from 0% in 2018 to 23.9% in 2023;
- The originator agent decreased from 14.9% to 11.9% during the same timeframe.
In the mCRC cohort, the proportion of patients using:
- The biosimilar agent increased from 0% in 2018 to 21.8% in 2023;
- The originator agent decreased from 22.9% to 7.4% during the same timeframe.
Hemorrhage was more common with the biosimilar bevacizumab than the originator biologic in the NSCLC cohort (6.4% vs 4.7%; P<0.001); however, the inverse was true in the mCRC group (9.9% vs 9.1%, respectively; P=0.008).
Median overall survival was 25.8 months for NSCLC and 29.5 months for mCRC.
“Bevacizumab originators and biosimilars are used by similar patient profiles, resulting in similar outcomes,” the author concluded.
Reference
Dixon R. Real-world bevacizumab biosimilar uptake from 2018 to 2023 and outcomes among patients with non-small cell lung cancer and metastatic colorectal cancer using commercial and Medicare Advantage claims in the United States. Abstract C2. Presented at AMCP 2025; March 31–April 3, 2025; Houston.
